Xu Peng-Peng相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial

Tucidinostat Plus R-CHOP vs R-CHOP 治疗 MYC/BCL2 双表达弥漫性大 B 细胞淋巴瘤：一项随机临床试验

期刊:Journal of the American Medical Association

影响因子:55

doi:10.1001/jama.2026.4199

Xu, Peng-Peng; Song, Yu-Qin; Shen, Jian-Zhen; Cai, Qing-Qing; Zhou, Hui; Zhang, Li-Ling; Xiang, Ying; Sun, Xiu-Hua; Yang, Wei; Yao, Zhi-Hua; Jing, Hong-Mei; Wen, Shu-Juan; Jin, Jie; Xue, Hong-Wei; Cen, Hong; Ding, Kai-Yang; Jin, Zheng-Ming; Liu, Li-Hong; Xing, Xiao-Jing; Li, Lan-Fang; Hou, Ming; Liu, Lin; Zhang, Ming-Zhi; Li, Wen-Yu; Bai, Ou; Feng, Ru; Zhu, Zun-Min; Wu, Hui-Jing; Su, Li-Ping; Gao, Li; Li, Fei; Huang, Wen-Rong; Liu, Peng; Yan, Xiao-Jing; Zhao, Ying; Su, Hang; Zhao, Xie-Lan; Fu, Rong; Liu, Hong; Shi, Wen-Yu; Li, Hui-Zhi; Chen, Bo; Ning, Zhi-Qiang; Zhu, Jun; Zhao, Wei-Li

细胞生物学

发表日期：2026

文献求助收藏

Correction: CircEAF2 counteracts Epstein-Barr viruspositive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis

更正：CircEAF2通过miR-BART19-3p/APC/β-catenin轴抑制Epstein-Barr病毒阳性弥漫性大B细胞淋巴瘤的进展。

期刊:Molecular Cancer

影响因子:33.9

doi:10.1186/s12943-026-02592-y

Zhao, Chen-Xing; Yan, Zi-Xun; Wen, Jing-Jing; Fu, Di; Xu, Peng-Peng; Wang, Li; Cheng, Shu; Hu, Jian-da; Zhao, Wei-Li

细胞生物学

免疫/内分泌

发表日期：2026

文献求助收藏

Genetic and Transcriptomic Profiles Identify Potential Therapeutic Targets of Concurrent Follicular and Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma.

基因和转录组谱分析揭示了同时发生的滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤以及转化型滤泡性淋巴瘤的潜在治疗靶点。

期刊:Hematological Oncology

影响因子:3.9

doi:10.1002/hon.70188

Sun Rui, Li Rui-Chi, Li Hui-Ying, Wang Nan, Xu Tian-Yuan, Tian Shuang, Fu Di, Li Chen, Zhang Fang-Yi, Feng Yan, Cheng Shu, Xu Peng-Peng, Wang Li, Zheng Zhong, Zhao Wei-Li

细胞生物学

免疫/内分泌

发表日期：2026

文献求助收藏

Association between the C-reactive protein-triglyceride-glucose index and asthma risk: evidence from the NHANES cohort and validation in the CHNS cohort

C反应蛋白-甘油三酯-葡萄糖指数与哮喘风险的关联：来自NHANES队列的证据和CHNS队列的验证

doi:10.1016/j.clinsp.2026.100965

Qian, Junmin; Xu, Peng; Peng, Ziying; Xia, Zuoxun

发表日期：2026

文献求助收藏

Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large B cell lymphoma: a phase 2 investigator-initiated nonrandomized clinical trial (GUIDANCE-06)

基因亚型指导的免疫化疗治疗复发难治性弥漫性大B细胞淋巴瘤：一项由研究者发起的2期非随机临床试验（GUIDANCE-06）

期刊:Signal Transduction and Targeted Therapy

影响因子:52.7

doi:10.1038/s41392-025-02316-6

Shen, Yi-Ge; Shi, Qing; Tang, Wei; Xu, Peng-Peng; Cao, Yi-Wen; Ji, Meng-Meng; Zheng, Zhong; Cheng, Shu; Wang, Li; Zhao, Wei-Li

细胞生物学

免疫/内分泌

发表日期：2025

文献求助收藏

Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study

结外弥漫性大B细胞淋巴瘤：多中心EXPECT研究的临床和分子见解及生存结果

期刊:Cancer Communications

影响因子:24.9

doi:10.1002/cac2.70033

Chen, Si-Yuan; Xu, Peng-Peng; Feng, Ru; Cui, Guo-Hui; Wang, Li; Cheng, Shu; Mu, Rong-Ji; Zhang, Hui-Lai; Wei, Xiao-Lei; Song, Yong-Ping; Ding, Kai-Yang; Dong, Li-Hua; Zhu, Zun-Min; Yang, Shen-Miao; Wang, Xin; Liu, Ting-Bo; Hu, Jian-Da; Zheng, Xiao-Yun; Bai, Ou; Xu, Jing-Yan; Huang, Liang; Sang, Wei; Shi, Ke-Qian; Zhou, Fan; Li, Fei; Liang, Ai-Bin; Zhou, Hui; Hao, Si-Guo; Huang, Hong-Hui; Xu, Bin; Qian, Wen-Bin; Li, Cai-Xia; Li, Zhi-Ming; Wu, Chong-Yang; Wang, Xiao-Bo; Shi, Wen-Yu; Wang, Shu-Ye; Tian, Yu-Yang; Zhang, Xi; Zhou, Ke-Shu; Cui, Li-Juan; Liu, Hui; Tan, Huo; Leng, Qing; Zhao, Dong-Lu; Niu, Ting; Zhao, Wei-Li

细胞生物学

免疫/内分泌

发表日期：2025

文献求助收藏

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma.

一项针对新发弥漫性大B细胞淋巴瘤的 2 期研究，评估 zanubrutinib 与利妥昔单抗和来那度胺联合用药的疗效。

影响因子:23.1

doi:10.1182/blood.2025028649

Xu Peng-Peng, Zhu Yue, Shi Zi-Yang, Wang Li, Cheng Shu, Qian Ying, Zhao Yan, He Yang, Yi Hong-Mei, Ou-Yang Bin-Shen, Jiang Xu-Feng, Li Biao, Song Qi, Mu Rong-Ji, Zhao Wei-Li

细胞生物学

发表日期：2025

文献求助收藏

Integration of gene mutations in risk prognostication for watch-and-wait follicular lymphoma patients initiating first-line treatment

将基因突变整合到观察等待策略下滤泡性淋巴瘤患者一线治疗的风险预后评估中

期刊:Hemasphere

影响因子:14.6

doi:10.1002/hem3.70141

Xu, Tian-Yuan; Mu, Rong-Ji; Zhang, Hui-Lai; Xu, Bing; Li, Rong; Wang, Nan; Sun, Rui; Li, Rui-Chi; Fu, Di; Wang, Xian-Huo; Li, Zhi-Feng; Zhao, Yan; Xu, Peng-Peng; Cheng, Shu; Wang, Li; Tang, Wei; Zheng, Zhong; Zhao, Wei-Li

发表日期：2025

文献求助收藏

Clinical characteristics and molecular heterogeneity in Follicular lymphoma with extranodal involvement

滤泡性淋巴瘤伴结外侵犯的临床特征和分子异质性

期刊:Genome Medicine

影响因子:11.2

doi:10.1186/s13073-025-01557-y

Li, Rui-Chi; Tang, Wei; Zhang, Hui-Lai; Wang, Xian-Huo; Sun, Rui; Wang, Nan; Xu, Tian-Yuan; Chen, Si-Yuan; Feng, Yan; Shen, Rong; Wang, Li; Cheng, Shu; Xu, Peng-Peng; Yi, Hong-Mei; Dong, Lei; Zheng, Zhong; Zhao, Wei-Li

发表日期：2025

文献求助收藏

Molecular heterogeneity of CD30(+) peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre study

CD30(+)外周T细胞淋巴瘤的分子异质性及其预后意义和治疗策略：一项回顾性多中心研究

期刊:EBioMedicine

影响因子:10.8

doi:10.1016/j.ebiom.2025.105693

Huo, Yu-Jia; Cheng, Shu; Yi, Hong-Mei; Niu, Ting; Fan, Lei; Cui, Guo-Hui; Zhou, Fu-Ling; Song, Xian-Min; Li, Fei; Bai, Ou; Yan, Xiao-Jing; Shi, Jun; Cai, Ming-Ci; Huang, Yao-Hui; Dong, Lei; Xiong, Jie; Hu, Song; Qiu, Yu-Ran; Zhao, Yan; Xu, Peng-Peng; Wang, Li; Lu, Min; Jing, Hong-Mei; Zhao, Wei-Li

细胞生物学

免疫/内分泌

发表日期：2025

文献求助收藏